Страна: Канада
Язык: английский
Источник: Health Canada
CEFTRIAXONE (CEFTRIAXONE SODIUM)
BAXTER CORPORATION
J01DD04
CEFTRIAXONE
1000MG
SOLUTION
CEFTRIAXONE (CEFTRIAXONE SODIUM) 1000MG
INTRAVENOUS
15G/50G
Prescription
THIRD GENERATION CEPHALOSPORINS
Active ingredient group (AIG) number: 0117292011; AHFS:
APPROVED
2020-06-02
PRODUCT MONOGRAPH Including Patient Medication Information PR CEFTRIAXONE INJECTION, USP CEFTRIAXONE (AS CEFTRIAXONE SODIUM USP) 1000 MG / 50 ML AND 2000 MG / 50 ML IN SINGLE DOSE GALAXY CONTAINERS READY-TO-USE STERILE SOLUTION (FROZEN) ANTIBIOTIC BAXTER CORPORATION 7125 Mississauga Road Mississauga, Ontario L5N 0C2 CONTROL #: 215096 Date of Preparation: May 28, 2020 BAXTER AND GALAXY ARE REGISTERED TRADEMARKS OF BAXTER INTERNATIONAL INC. Ceftriaxone Injection, USP Page 2 of 52 TABLE OF CONTENTS HEALTH PROFESSIONAL INFORMATION ......................................................................... 3 ACTION ...................................................................................................................................... 3 INDICATIONS AND CLINICAL USES ................................................................................... 3 CONTRAINDICATIONS ........................................................................................................... 4 WARNINGS ............................................................................................................................... 4 PRECAUTIONS ......................................................................................................................... 7 ADVERSE REACTIONS ........................................................................................................... 8 SYMPTOMS AND TREATMENT OF OVERDOSAGE ........................................................ 10 DOSAGE AND ADMINISTRATION ..................................................................................... 10 ADMINISTRATION ................................................................................................................ 11 SPECIAL HANDLING INSTRUCTIONS ............................................................................... 12 PHARMACEUTICAL INFORMATION ................................................................................. 13 DRUG SUBSTANCE ................................................................. Прочитать полный документ